Status:

COMPLETED

A Study To Investigate The Effect Of PD-217,014 On Abdominal Pain/Discomfort In Patients With IBS.

Lead Sponsor:

Pfizer

Conditions:

Irritable Bowel Syndrome

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to determine the effectiveness of PD-217,014 in the treatment of abdominal pain/discomfort associated with irritable bowel disease.

Eligibility Criteria

Inclusion

  • Males and females having Irritable bowel syndrome as defined by the Rome II criteria.
  • Patients must have had normal examination of colon anatomy within the last 5 years

Exclusion

  • Patient with an organic gastrointestinal disease.
  • Patients with poor renal function.
  • Patients with severe constipation.

Key Trial Info

Start Date :

January 1 2004

Trial Type :

INTERVENTIONAL

End Date :

February 1 2005

Estimated Enrollment :

330 Patients enrolled

Trial Details

Trial ID

NCT00139672

Start Date

January 1 2004

End Date

February 1 2005

Last Update

June 17 2008

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.